ADC Therapeutics, Sobi Ink European Licensing Pact For Lymphoma Drug
ADC Therapeutics SA (NYSE:ADCT) has entered into an exclusive license agreement with Swedish Orphan Biovitrum AB (OTC:BIOVF) for the development and commercialization of…
Redburn Partners Downgrades PayPal Holdings to Neutral
Redburn Partners analyst Fahed Kunwar downgrades PayPal Holdings (NASDAQ:PYPL) from Buy to Neutral.
Citigroup Downgrades Agilent Technologies to Neutral, Lowers Price Target to $140
Citigroup analyst Patrick Donnelly downgrades Agilent Technologies (NYSE:A) from Buy to Neutral and lowers the price target from $175 to $140.
Buyer Consortium Led By Recco Control Technology And Dazheng Group Announces Engagement Of UBS As Financial Advisor And Reaffirms Non-Binding Indicative Offer Of $25 Per Share To Acquire Hollysys
Buyer consortium led by Recco Control Technology Pte. Ltd. ("Recco Control Technology") and Dazheng Group (Hong Kong) Investment Holdings Company Limited ("Dazheng Group") announces today that
Piper Sandler Maintains Overweight on Globe Life, Raises Price Target to $121
Piper Sandler analyst John Barnidge maintains Globe Life (NYSE:GL) with a Overweight and raises the price target from $119 to $121.
Piper Sandler Maintains Neutral on CNO Finl Group, Lowers Price Target to $19
Piper Sandler analyst John Barnidge maintains CNO Finl Group (NYSE:CNO) with a Neutral and lowers the price target from $22 to $19.
Piper Sandler Maintains Neutral on Brighthouse Finl, Lowers Price Target to $43
Piper Sandler analyst John Barnidge maintains Brighthouse Finl (NASDAQ:BHF) with a Neutral and lowers the price target from $50 to $43.
Piper Sandler Maintains Underweight on Ameriprise Financial, Lowers Price Target to $231
Piper Sandler analyst John Barnidge maintains Ameriprise Financial (NYSE:AMP) with a Underweight and lowers the price target from $253 to $231.
Piper Sandler Maintains Overweight on Aflac, Lowers Price Target to $66
Piper Sandler analyst John Barnidge maintains Aflac (NYSE:AFL) with a Overweight and lowers the price target from $68 to $66.
Optinose Announces Additional Results From ReOpen2 And Initial Results From Pooled Analyses Of Both Trials In The ReOpen Program
Company previously announced positive top-line results from both ReOpen1 and ReOpen2, the landmark trials evaluating XHANCE as a treatment for chronic sinusitis
Multiple secondary endpoints from ReOpen2 indicate